You are here

Article Text

Article menu
Download PDFPDF
Editorial
Obesity and GLP-1 RAs
  1. Tamis Bright
  1. Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA
  1. Correspondence to Dr Tamis Bright, Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA; tamis.bright{at}ttuhsc.edu

http://dx.doi.org/10.1136/jim-2021-002268

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In this issue of the Journal of Investigative Medicine, Singh et al review the important addition of the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of obesity and specifically discuss semaglutide for weight management. Despite the dire and costly outcomes of obesity, the USA and much of the world have failed for years to practice healthy eating and exercise. The 2017–2018 National Health and Nutrition Examination Survey (NHANES) estimated that 42.5% of US adults aged 20 and over have obesity and an additional 31.1% are overweight, impacting 73.6% of the adult population.1

    Having excessive weight has now become the “norm” with those overweight or …

    View Full Text

    Footnotes

    • Contributors TB is the sole contributor.

    • Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles